Cargando…

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Suárez, Cristina, Nolder, Debbie, García-Mingo, Ana, Moore, David A J, Chiodini, Peter L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326036/
https://www.ncbi.nlm.nih.gov/pubmed/35912165
http://dx.doi.org/10.2147/RRTM.S278135
_version_ 1784757186461696000
author Suárez, Cristina
Nolder, Debbie
García-Mingo, Ana
Moore, David A J
Chiodini, Peter L
author_facet Suárez, Cristina
Nolder, Debbie
García-Mingo, Ana
Moore, David A J
Chiodini, Peter L
author_sort Suárez, Cristina
collection PubMed
description Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review proposes strategies to address challenges faced by non-endemic countries.
format Online
Article
Text
id pubmed-9326036
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93260362022-07-28 Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas Suárez, Cristina Nolder, Debbie García-Mingo, Ana Moore, David A J Chiodini, Peter L Res Rep Trop Med Review Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review proposes strategies to address challenges faced by non-endemic countries. Dove 2022-07-22 /pmc/articles/PMC9326036/ /pubmed/35912165 http://dx.doi.org/10.2147/RRTM.S278135 Text en © 2022 Suárez et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Suárez, Cristina
Nolder, Debbie
García-Mingo, Ana
Moore, David A J
Chiodini, Peter L
Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title_full Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title_fullStr Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title_full_unstemmed Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title_short Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
title_sort diagnosis and clinical management of chagas disease: an increasing challenge in non-endemic areas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326036/
https://www.ncbi.nlm.nih.gov/pubmed/35912165
http://dx.doi.org/10.2147/RRTM.S278135
work_keys_str_mv AT suarezcristina diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas
AT nolderdebbie diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas
AT garciamingoana diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas
AT mooredavidaj diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas
AT chiodinipeterl diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas